Printer Friendly Version View printer-friendly version
<< Back
Mediclinic Intnl plc - Annual Financial Report
RNS Number : 0149J
Mediclinic International plc
23 June 2017
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

23 June 2017

 

POSTING OF ANNUAL REPORT AND FINANCIAL STATEMENTS, NOTICE OF ANNUAL GENERAL MEETING AND PROXY FORM

 

Mediclinic's Annual Report and Financial Statements in respect of the financial year ended 31 March 2017 ("2017 Annual Report") is being posted to shareholders during the course of today, together with the Notice of Annual General Meeting and Form of Proxy in relation to the Company's annual general meeting to be held on Tuesday, 25 July 2017 at the Rosewood London Hotel, 252 High Holborn, London, WC1V 7EN at 15:00 (BST).

 

In accordance with Listing Rule 9.6.1, the above documents will be submitted to the UK Listing Authority via a National Storage Mechanism and will shortly be available to the public for inspection at www.morningstar.co.uk/NSM.

 

The documents will also be made available on the Company's website at www.mediclinic.com during the course of today.

 

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

 

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

 

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

+44 (0)207 954 9600

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000

 

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 



APPENDICES

The following appendices should be read in conjunction with, and not as a substitute for, reading the full 2017 Annual Report. Take note that page references and definitions in the text below are as in the 2017 Annual Report.

 

APPENDIX A: PRINCIPAL RISKS

The Company's principal risks are detailed below. For further information on the risks for the financial year ended 31 March 2017, please refer to the 2017 Annual Report. 

 

PRINCIPAL RISK

DESCRIPTION OF RISK

MITIGATION OF RISK

Regulatory and Compliance risk

 

Adverse changes in laws and regulations impacting the Group or the failure to comply with laws and regulations which may result in losses, fines, prosecution or damage to reputation.

 

The risk includes ethical and governance risks that refer to unexpected negative consequences of unethical actions or the failure of the control and oversight mechanisms which were designed and implemented to uphold the ethical standards and controls of the organisation.

 

·    Proactive engagement strategies with stakeholders

·    Health policy units created to conduct research and provide strategic input for reform processes

·    Active industry participation across all platforms

·    Company secretarial and legal departments support operational management, monitor regulatory developments and, where necessary, obtain expert legal advice for the effective implementation of compliance initiatives

·    Compliance risks identified and assessed as part of departmental risk registers

·    Compliance management

·    Visible ethical leadership

·    Monitoring and investigation of incidents reported on the ethics line

·    Board-level oversight

Competition

 

The risk relating to the uncertainty created by the existence of competitors or the emergence of new competitors with their own strategies.

 

The risk includes the outmigration of care, partly driven by further technological developments and the development of alternative care models.

·    Proactive monitoring

·    Strategic planning processes

·    Quality and value of care processes

Business investment and acquisition risks

 

 

The increased financial exposure relating to major strategic business investments and acquisitions.

 

During the prior financial year, Mediclinic made strategic investments in Spire Healthcare, and acquired the Al Noor Hospitals Group.

·    Strategic planning processes

·    Due diligence processes

·    Investment mandates

·    Board oversight

·    Post-acquisition management processes

 

Economic and business environment

 

 

The downturn in the general economic and business environment, including all those factors that affect a company's operations, customers, competitors, stakeholders, suppliers and industry trends.

 

The business environment risk includes the power of funders and the potential negative impact on tariffs and fees resulting from the shift of the relative negotiating power towards funders, away from healthcare service providers.

·    Systems to monitor developments in the economic and business environment of trends and early warning indicators

·    Proactive monitoring and negotiation by Group's funder relations departments

·    Focus on quality and continuum of care to reinforce the Company's position

Operational and credit risks

 

Operational risk refers to various types of operational events with a potential for financial loss.

 

Credit risk is the risk of loss due to a funder's inability to pay the outstanding balance owing, default by banks and/or other deposit-taking institutions, or the inability to recover outstanding amounts due from the patient.

·    Preservation of a sound internal financial control environment

·    Effective risk management processes

·    Extensive combined assurance processes

·    Monitoring operations through KPIs

·    Continuous enhancement of operational efficiency and cost reduction

·    Regulated minimum solvency requirements for funders

·    Monitoring approved funders

·    Treasury policy

·    Board-level oversight

Availability and cost of capital

(Including financing and liquidity risk)

 

The cost, terms and availability of capital to finance strategic expansion opportunities and/or the refinancing or restructuring of existing debt which was affected by prevailing capital market conditions.

 

The impact of negative interest rates currently prevalent in Switzerland.

·    Long-term planning of capital requirements and cash-flow forecasting

·    Scrutiny of cash-generating capacity within the Group

·    Proactive and long-term agreements with banks and other funders relating to funding facilities

·    Monitoring compliance with requirements of debt covenants

·    Further details on capital risk management and the Group's borrowings are contained in the consolidated financial statements on page 164

Clinical risks

 

All clinical risks associated with the provision of clinical care resulting in undesirable clinical care or clinical outcomes.

 

The risks include a pandemic and disease outbreak.  A pandemic is an epidemic of infectious disease that is spreading through human populations across a large region. Disease outbreak involves highly infectious diseases with a high mortality rate.

 

Such risks may also result in damage to the Mediclinic brand equity. Brand equity refers to the value of the Group's brand names.

·    Refer to the Clinical Services Overview from page 37 and the Clinical Services Report available on the Company's website at www.mediclinic.com for a detailed analysis of the strategies to manage and monitor clinical risks

·    A Group-wide clinical risk register implemented per platform

·    Accreditation processes

·    Clinical governance processes

·    Monitoring clinical performance indicators

·    Implementation of comprehensive processes for infection control and prevention

·    Marketing and communication strategies

·    Focus on quality management processes

·    Stakeholder engagement and disclosure strategies

Information systems security and availability risk

Information systems security risk (including cyber risk) relates to the unauthorised access to information systems, failure of data integrity and confidentiality. Availability risk relates to the instances where systems are not available for use by its intended users.

 

A risk which closely associated with information systems risk is project delivery. Project delivery risk refers to issues or occurrences that may potentially interfere with successful completion of projects, including its scope, timeliness and appropriateness of delivery.

·    Comprehensive IT logical access, change and physical access controls

·    Disaster recovery planning

·    System design and architecture

·    Group ICT security committee

·    Experienced project management team

·    Proactive monitoring and oversight

·    Reallocation of tasks and resources

 

Quality and stability of operational services

 

The risk refers to the quality of service and the stability of the operations. It includes but is not limited to:

·      incidents of poor service or incidents where operational management fail to respond effectively to complaints;

·      operational interruptions which are any disruption of the facility and including the threat of disrupted power or water supply; and

·      fire and allied perils causing damage or business interruption.

·    Patient satisfaction surveys (both internal and external)

·    Complaints monitoring

·    Training programmes

·    Supervision of service levels

·    Emergency backup power generation

·    Emergency planning

·    Plans to deal with disasters

·    Extensive fire-fighting and detection systems, including comprehensive maintenance processes

·    Comprehensive insurance to deal with financial impact of potential disasters

Availability, recruitment and retention of skilled resources and medical practitioners

 

 

The availability and support of admitting doctors, whether independent or employed, are critical to the services the Group provides.

 

There is a shortage of skilled labour, particularly a shortage of qualified and experienced nursing staff in Southern Africa.

·    Monitoring doctor satisfaction, movement and doctors' profiles

·    Details on the relationship with doctors are provided in the Sustainable Development Report available on the Company's website at www.mediclinic.com

·    The employment recruitment and retention strategies are explained in the Sustainable Development Highlights on page 60 and in more detail in the Sustainable Development Report available on the Company's website at www.mediclinic.com

·    Extensive training and skills development programme, and foreign recruitment program, further explained in the Sustainable Development Highlights on page 61 and in more detail in the Sustainable Development Report available on the Company's website at www.mediclinic.com

 



APPENDIX B: RELATED-PARTY TRANSACTIONS

 

 



GROUP



2017

GBP'm

2016

GBP'm

34.

RELATED-PARTY TRANSACTIONS

 

 




The following transactions were carried out with related third parties:







i)

Transactions with shareholders

 




Share subscription - Remgro Group and its subsidiaries

-

600


In addition to the share subscription (February 2016), Remgro also participated in the Right Offer (August 2015)








Remgro Management Services Limited (subsidiary of Remgro Limited)




- Managerial and administration fees

0.30

0.20


- Internal audit services

0.20

0.10


- Management fee relating to the acquisition of equity investment

(Spire Healthcare Group plc)

-

2


- Underwriting fees in respect of the rights offer

-

4






V & R Management Services AG (subsidiary of Remgro Limited)




- Administration fees*

-

-






Acquisition of equity investment (Spire Healthcare Group plc)










ii)

Key management compensation

 




Key management includes the directors (executive and non-executive) and members of the executive committee.




Salaries and other short-term benefits

7

4


- Short-term benefits

6

4


- Post-employment benefits*

-

-


- Share-based payment

1

-





iii)

Transactions with associates

 




Zentrallabor Zürich (ZLZ)




- Fees earned

(1)

(1)


- Purchases

10

7






Spire Healthcare Group plc




- Non-executive director fee*                                                           

*amount is less than £0.5m.

-

-

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSSELSUDFWSELM

IMPORTANT DISCLAIMER

ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS, RULES OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT OR PHYSICALLY PRESENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY, OR DISTRIBUTED OR DISSEMINATED TO, DIRECTLY OR INDIRECTLY, PERSONS RESIDENT OR PHYSICALLY LOCATED IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS, RULES OR REGULATIONS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH CONSENT OR OTHER FORMALITY WHICH MEDICLINIC REGARDS AS UNDULY ONEROUS.

Combination of Mediclinic International Limited ("Mediclinic") and Al Noor Hospitals Group plc ("Al Noor") (the "Combination")

Access to the website

You are attempting to enter the part of the website that is designated for the publication of documents and information in connection with the Combination.

If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. Mediclinic reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of Mediclinic.

This part of the website contains electronic versions of materials relating to the Combination. The materials you are seeking to access are made available in good faith and for information purposes only and are subject to the terms and conditions set out below. Any person seeking to access this part of the website represents and warrants to Mediclinic that they are doing so for information purposes only.

To allow you to view information about the Combination, you must read this notice and then click "I ACCEPT". If you are unable to agree, you should click "I DECLINE" and you will not be able to view information about the Combination.

The Combination would be made by means of a scheme document to be published by Mediclinic which would contain the full terms and conditions of such Combination, including details on how it may be accepted. Any decision made in relation to the Combination should be made solely and only on the basis of the information provided in any such document.

Overseas jurisdictions

Viewing the materials you are seeking to access may be restricted under securities laws in certain jurisdictions. All persons who wish to view this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.

These materials are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS PART OF THE WEBSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO. MEDICLINIC AND ITS ADVISERS DO NOT ASSUME ANY LIABILITY FOR ANY VIOLATION BY ANY PERSON OF ANY OF THESE RESTRICTIONS.

It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should click on “I DECLINE” below and exit this webpage.

Cautionary Note Regarding Forward-Looking Statements

This part of the website and the information contained in it may contain certain forward-looking statements with respect to the financial condition, results of operations and businesses of Mediclinic and the Mediclinic Group (being Mediclinic and its subsidiaries and subsidiary undertakings) and Al Noor and the Al Noor Group (being Al Noor and its subsidiaries and subsidiary undertakings) following the Combination. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic and the Mediclinic Group to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases. There are a number of factors that could affect the future operations of Mediclinic and the Mediclinic Group and Al Noor and the Al Noor Group post Combination and could cause those results to differ materially from those expressed in the forward-looking statements included in this part of the website. All forward-looking statements contained in this part of the website are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as at the specified date of the relevant document within which the statement is contained. None of Mediclinic, the Mediclinic Group, Al Noor or the Al Noor Group undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this part of the website.

Responsibility

In relation to any Combination-related materials accessible on this area of the website please note any statement of responsibility contained therein.

The documents included in this part of the website issued or published by Mediclinic speak only at the specified date of the relevant document and Mediclinic has, and accepts, no responsibility or duty to update or revise such documents.

In relation to any such announcements or other Combination-related materials issued or published by Al Noor, or which relate to Al Noor and the Al Noor Group, that are accessible on this website, the only responsibility accepted by Mediclinic and its directors is for the correctness and fairness of its reproduction.

Neither the directors of Mediclinic, nor Mediclinic, nor any of their affiliated companies, have reviewed, and no such person is or shall be responsible for or accepts any liability in respect of, any information contained on any other website which may be linked to or from this part of the website.

Other

If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an appropriately authorised independent financial adviser.

This notice shall be governed by and construed in accordance with English law.

CONFIRMATION OF UNDERSTANDING AND ACCEPTANCE

If you are not able to give these confirmations, you should click on “I DECLINE” below and exit the webpage.